Soligenix announces positive clinical results from a comparative study evaluating hybryte™ against valchlor® in the treatment of cutaneous t-cell lymphoma

Hybryte™ demonstrates more rapid and robust treatment response compared to valchlor® during 12-week treatment course princeton, n.j. , june 25, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a comparability study evaluating hybryte™ (synthetic hypericin) versus valchlor® (mechlorethamine gel) in the treatment of cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking